Oct 2 (Reuters) - Germany's Boehringer Ingelheim on Monday launched an unbranded version of its biosimilar of AbbVie's (ABBV.N), opens new tab Humira with a list price 81% cheaper than the blockbuster ...

This year, CVS Health plans to employ the classic "out with the old, in with the new" mantra when it comes to AbbVie’s Humira. Come April 1, the branded drug will be replaced by cheaper biosimilars ...

Tennessee last year spent $48 million on a single drug, Humira — about $62,000 for each of the 775 patients who were covered by its employee health insurance program and receiving the treatment. So ...

The net prices that health plans paid for medicines — after subtracting rebates, discounts, and fees — fell by 2.8% in last year’s fourth quarter, the largest decline ever measured by SSR Health, a ...

(Reuters) - AbbVie’s top-selling arthritis drug Humira has held onto more than 80% of patients after facing nine lower-priced rivals in the U.S. in the last year, raising questions about whether the ...

The US FDA has already approved two directly interchangeable biosimilars to ABBV's Humira, namely Boehringer Ingelheim's Cyltezo and PFE's ABRILADA. The impact on ABBV's sales may be great, since its ...

A long-awaited moment for consumers arrived last year when patent protection expired on the nation’s most prescribed medicine, AbbVie’s wildly successful — and costly — rheumatoid arthritis drug ...

A top California health plan is set to offer one of the world’s biggest-selling drugs for free in a bid to show the medicine can reach Americans affordably without going through the middlemen that ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The first Humira biosimilar hit the U.S. market a little ...